The purpose of this prospective, randomised, multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) in preventing graft rejection and in improving clear graft survival ...

Triple-drug immunosuppression regimens including mycophenolate mofetil, taken for ≥6 months are associated with reduced rates of LAR; further studies are needed to define optimal immunosuppression ...

The European Medicines Agency (EMA) has issued updated recommendations for contraception in men and women taking mycophenolate medicines to prevent rejection of transplanted organs. The ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Mycophenolate mofetil (MMF, CellCept) was effective in halting rapidly progressive diffuse cutaneous systemic sclerosis (SSc), but a substantial percentage of patients experienced recurrences when the ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. However, withholding mycophenolate mofetil for 1 week ...

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted. Mycophenolate mofetil (MMF) reduces the risk of disease progression in patients with immunoglobulin A ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. On June 3, ...

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...